Abstract
There are few data on mortality after discharge with community-acquired pneumonia (CAP). Therefore, we evaluated risk factors for 30-day post-discharge mortality after CAP. We included all patients of the prospective multi-national CAPNETZ study between 2002 and 2018 with (1) hospitalized CAP, (2) survival until discharge, and (3) complete follow-up data. The study endpoint was death within 30 days after discharge. We evaluated risk factors including demographics, comorbidities, admission CAP severity, and laboratory values and treatment-related factors in uni- and multivariable analyses. A total of 126 (1.6%) of 7882 included patients died until day 30 after discharge, corresponding to 26% of all 476 deaths. After multivariable analysis, we identified 10 independent risk factors: higher age, lower BMI, presence of diabetes mellitus, chronic renal or chronic neurological disease (other than cerebrovascular diseases), low body temperature or higher thrombocytes on admission, extended length of hospitalization, oxygen therapy during hospitalization, and post-obstructive pneumonia. By addition these factors, we calculated a risk score with an AUC of 0.831 (95%CI 0.822–0.839, p < 0.001) for prediction of post-discharge mortality. Early post-discharge deaths account for ¼ of all CAP-associated deaths and are associated with patient- and CAP-severity-related risk factors. Additional studies are necessary to replicate our findings in independent cohorts. Study registration: NCT 02139163.
| Original language | English |
|---|---|
| Journal | European Journal of Clinical Microbiology and Infectious Diseases |
| Volume | 41 |
| Issue number | 4 |
| Pages (from-to) | 621-630 |
| Number of pages | 10 |
| ISSN | 0934-9723 |
| DOIs | |
| Publication status | Published - 04.2022 |
Funding
Dr. Witzenrath reports grants from Deutsche Forschungsgemeinschaft, Bundesministerium für Bildung und Forschung, Marie Curie Foundation, Capnetz Stiftung, Noxxon, Pantherna, Vaxxilon, Bayer Health Care, Biotest; and consulting fees or honoraria from Noxxon, Pantherna, Silence Therapeutics, Vaxxilon, Aptarion, Glaxo Smith Kline, Sinoxa, Biotest, Astra Zeneca, Berlin Chemie, Chiesi, Novartis, Teva, Actelion, Boehringer Ingelheim, and Bayer Health Care, all outside the submitted work. Open Access funding enabled and organized by Projekt DEAL. CAPNETZ was founded by a German Federal Ministry of Education and Research grant (01KI07145) 2001–2011. MWP is partly supported by a grant of the Federal Ministry of Education and Research KliFo 2.0 (grant number 01KI1501).
Research Areas and Centers
- Academic Focus: Center for Infection and Inflammation Research (ZIEL)